Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. - Wikidata - wikimedia - TriplyDB

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

http://www.wikidata.org/entity/Q37033867

about

Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus.Monocyte Siglec-14 expression is upregulated in patients with systemic lupus erythematosus and correlates with lupus disease activity.The interplay between Siglecs and sialylated pathogens Association of serum interleukin-27 with the exacerbation of chronic obstructive pulmonary disease Siglec-mediated regulation of immune cell function in disease.Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasminogen levels.Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec-5 and Siglec-14.Associations of genetic polymorphisms of Siglecs with human diseases.Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency.Increased expression of Siglec-9 in chronic obstructive pulmonary disease.SAMP-ending down sepsis.Coevolution of Siglec-11 and Siglec-16 via gene conversion in primates.Sialic Acids in the Immune Response during Sepsis.Long Noncoding RNAs and mRNA Regulation in Peripheral Blood Mononuclear Cells of Patients with Chronic Obstructive Pulmonary Disease.

P2860

Q33702945-405A5742-4AAC-4135-B8F9-EC1BD47E6A55 Q33731305-3E683352-0DEB-46E9-9F92-2246A7A6DBC0 Q34208951-3941E891-634F-4FF1-A64A-4769EFF33129 Q34297424-39D722A8-6ED1-4FDC-A883-730C1BD456F1 Q34314957-6B54F041-9C8B-443A-BFDA-0F524F936E39 Q34508365-51F9ABA6-8D9D-4EAE-B9BA-6D6846160C67 Q35164415-9D46A2CA-0500-4435-A145-F827E513CCF6 Q36380685-62DAA432-1802-4026-8492-F70847ABF44E Q38212860-74FE722F-4BAF-4EE5-A2CC-2A717D21895C Q38598881-E873F110-EFA2-4717-8F95-BB714B44FB09 Q38729391-F9454C54-D024-4C07-AF4F-96BE519BBCF8 Q40071781-1175754D-5D12-47AE-AC6C-DCF7BCD507B5 Q42330827-2DC862E3-FCB1-4B12-8C62-D42923E6C0EA Q46075546-130D22FF-B566-41FE-8032-9A848AFA41AF Q47098617-75B53EC4-89B9-42DD-8EA7-6FEC1BDF879A Q55279911-5CD3C040-FD4C-4A6A-B6FA-4C116377D7F2

P2860

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

http://www.wikidata.org/entity/Q37033867

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

@en

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

@nl

type

label

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

@en

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

@nl

prefLabel

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

@en

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation.

@nl

P1433

Q37033867-43CDE430-D21E-4043-8433-7265FCCFA1B6

P1476

Q37033867-171DE653-15AD-42CE-9317-2AE43A8A471B

P2093

Q37033867-01741D0C-E480-4EC5-8BA4-29004C0D883B

Q37033867-0B430FD7-EFDB-4CB0-8453-13AAB69EBAFC

Q37033867-1FC0B25C-9404-488C-81B8-F7DABFE1789D

Q37033867-297A158D-58F8-4F8A-AA17-FC51477F7C24

Q37033867-2A6C5D57-47AD-4EFC-96AA-C850C98B6E33

Q37033867-43D4DFE0-292C-4209-8EA5-86385A7FD550

Q37033867-4C4DECCC-17DD-4B4A-9CE6-E55E039AF9F3

Q37033867-6DAA49FE-6759-4FDE-B08F-4BFA31720A46

Q37033867-B649D418-1F58-4D28-83B5-FE15B6ED21DF

Q37033867-C760DFF7-7D55-4BD6-9DA9-49EC44C4F8DC

P2860

Q37033867-02EB964B-C5FA-4CDB-BE3C-B92EF1A04E2A

Q37033867-06E1AA1D-C188-4519-8987-0603A9C31075

Q37033867-08DACB34-955F-4486-907F-0AD22D0D9644

Q37033867-15CB9EF3-0D47-435A-8027-50EB69BA9325

Q37033867-18EBECF7-1794-4720-9DFD-2A050F099C7E

Q37033867-1D9B02DE-4BDB-4B50-AC6A-7986F0500BF0

Q37033867-24B7C1A0-9706-41AE-A4B9-19B7E9CEFECF

Q37033867-26616CBE-CC18-4F28-B11C-EF70257FB7FE

Q37033867-277EBED4-4461-4A55-A957-44D1789A708B

Q37033867-28BB1A67-6D5E-49D4-BFEB-70A7B4E595F4

P2888

Q37033867-D9AFA081-1C53-4736-8534-A57CD44FC7EA

P304

Q37033867-B3BF848F-3CE4-4D23-8E0C-FDA19C596302

P31

Q37033867-428C8122-363D-4808-A3EE-87F9E38411FB

P356

Q37033867-AC6884F9-F483-4AB3-941D-D8AE73DC3977

P433

Q37033867-34A3287D-665B-4BB4-AC04-BD852D8D9634

P478

Q37033867-FDE1A8F1-71D4-45CA-A366-5BB74FA912D5

P50

Q37033867-2BE21FC2-9D38-454B-AA45-E4DC9328161B

Q37033867-467C8088-2569-4F41-B169-60A3901D2D35

P577

Q37033867-F43CC185-187F-415B-99F3-A04A70660D3D

P5875

Q37033867-ED7FA0E9-AA87-446A-A97B-CC25FAD585C3

P698

Q37033867-EBA957F4-2209-42BC-B9FA-DE8D38D75AF3

P921

Q37033867-BB0AD5F7-79D0-4431-9A29-ADAF3DA95F0B

P932

Q37033867-2DC73FF4-DBEC-49F5-B42F-D27182109F8C

P356

S00018-013-1311-7

P1433

Cellular and Molecular Life Sciences

P1476

Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation

@en

P2093

Ajit Varki

http://www.w3.org/2001/XMLSchema#string

Akihiko Gemma

http://www.w3.org/2001/XMLSchema#string

Cong-Xiao Gao

http://www.w3.org/2001/XMLSchema#string

Ismael Secundino

http://www.w3.org/2001/XMLSchema#string

Kazuaki Ohtsubo

http://www.w3.org/2001/XMLSchema#string

Kozui Kida

http://www.w3.org/2001/XMLSchema#string

Naoyuki Taniguchi

http://www.w3.org/2001/XMLSchema#string

Paula Campos Soto

http://www.w3.org/2001/XMLSchema#string

Rachel E Taylor

http://www.w3.org/2001/XMLSchema#string

Ritsuko Oka

http://www.w3.org/2001/XMLSchema#string

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake

Siglecs--the major subfamily of I-type lectins

Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

Siglecs and their roles in the immune system

Standardization of Spirometry, 1994 Update. American Thoracic Society

Nontypeable Haemophilus influenzae strain 2019 produces a biofilm containing N-acetylneuraminic acid that may mimic sialylated O-linked glycans

A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci.

Toward a consensus definition for COPD exacerbations.

P2888

s00018-013-1311-7

P304

3199-3210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00018-013-1311-7

http://www.w3.org/2001/XMLSchema#string

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236071762

http://www.w3.org/2001/XMLSchema#string

P698

23519826

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

3718857

http://www.w3.org/2001/XMLSchema#string